Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of cardiovascular events in diabetics selected by elevated NT-proBNP
ChiCTR2000041466Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), heart failure (HF) and cardiac morbidity (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Cardiovascular events (hospitalization or death). Started Feb 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)cardiac morbidity
Beyond the preview
Go deeper on ChiCTR2000041466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041466.